Form 4 for AIM AIM ImmunoTech Inc.
Accepted 2025-04-23 00:00:00 ET · period of report 2025-04-21 · accession 0001641172-25-005861 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-23 | 2025-04-11 | AIM | Equels Thomas K | CEO, Pres, Dir | P - Purchase | $0.03 | +1.97M | 3.87M | +104% | +$59.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-11 | P | A | 1,968,504 | $0.03 | 3,867,533 | D | — | — | (F1) Shares purchased pursuant to a purchase agreement executed on April 11, 2025, but first required approval from the NYSE American which was received on April 21, 2025. |